Jul 22 2010
BioTime, Inc. (AMEX:BTIM) announced today that on August 1, 2010 the Company will be offering for sale 21 new stem cell products for research use only. These products will include the novel stem cell lines: E120 expressing the gene LGR5 useful in colon cancer drug discovery, EN16, T43, RAD20.5, RA-SKEL8, SM22, and Z1, full properties of which will be disclosed on product launch, along with differentiation kits and media for the culture of each line. BioTime CEO Dr. Michael West will discuss these new products as part of his presentation today on "Regenerative Medicine: Finding Opportunity in a Scientific Revolution" at the Agora Financial Investment Symposium 2010, July 20-23, at the Fairmont Hotel Vancouver. Additional information about the products may be found online at www.embryome.com/products.htm beginning August 1, 2010.
“Regenerative Medicine: Finding Opportunity in a Scientific Revolution”
Dr. West's presentation will address the state of the regenerative medicine industry in addition to the update on BioTime's 2010 product portfolio aimed at the near-term research market. Dr. West's presentation will be available online at www.biotimeinc.com.
The annual symposium this year by Agora Financial, LLC, will focus on the impact of the current economic and political climate on investment strategies. Agora Financial is an independent provider of economic forecasting and financial research.
SOURCE BioTime, Inc.
Researchers discover mechanism affecting splicing process in retinal cells